Table of Contents Author Guidelines Submit a Manuscript
Advances in Hematology
Volume 2013, Article ID 151506, 6 pages
http://dx.doi.org/10.1155/2013/151506
Research Article

Achievement of Therapeutic Goals with Low-Dose Imiglucerase in Gaucher Disease: A Single-Center Experience

1Shaare Zedek Medical Center, Affiliated to the Hadassah-Hebrew University School of Medicine, Ein Karem 91031, Israel
2Gaucher Clinic and Preimplantation Genetics Unit, Shaare Zedek Medical Center, Affiliated to the Hadassah-Hebrew University School of Medicine, Ein Karem 91031, Israel

Received 3 July 2013; Revised 8 September 2013; Accepted 15 September 2013

Academic Editor: David Varon

Copyright © 2013 Irina Tukan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Zimran and D. Elstein, “Lipid storage diseases,” in Williams Hematology, M. A. Lichtman, T. Kipps, U. Seligsohn, K. Kaushansky, and J. T. Prchal, Eds., pp. 1065–1071, McGraw-Hill, New York, NY, USA, 8th edition, 2010. View at Google Scholar
  2. N. W. Barton, R. O. Brady, J. M. Dambrosia et al., “Replacement therapy for inherited enzyme deficiency: macrophage-targeted glucocerebrosidase for Gaucher's disease,” The New England Journal of Medicine, vol. 324, no. 21, pp. 1464–1470, 1991. View at Google Scholar · View at Scopus
  3. G. A. Grabowski, N. W. Barton, G. Pastores et al., “Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources,” Annals of Internal Medicine, vol. 122, no. 1, pp. 33–39, 1995. View at Google Scholar · View at Scopus
  4. A. Zimran, D. Elstein, E. Levy-Lahad et al., “Replacement therapy with imiglucerase for type 1 Gaucher's disease,” The Lancet, vol. 345, no. 8963, pp. 1479–1480, 1995. View at Publisher · View at Google Scholar · View at Scopus
  5. N. J. Weinreb, J. Charrow, H. C. Andersson et al., “Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher registry,” The American Journal of Medicine, vol. 113, no. 2, pp. 112–119, 2002. View at Publisher · View at Google Scholar · View at Scopus
  6. N. J. Weinreb, “Advances in Gaucher disease: therapeutic goals and evaluation and monitoring guidelines,” Seminars in Hematology, vol. 41, no. 4, supplement 5, pp. 1–3, 2004. View at Google Scholar · View at Scopus
  7. G. M. Pastores, N. J. Weinreb, H. Aerts et al., “Therapeutic goals in the treatment of Gaucher disease,” Seminars in Hematology, vol. 41, no. 5, supplement 5, pp. 4–14, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Weinreb, J. Taylor, T. Cox, J. Yee, and S. vom Dahl, “A benchmark analysis of the achievement of therapeutic goals for type 1 Gaucher disease patients treated with imiglucerase,” The American Journal of Hematology, vol. 83, no. 12, pp. 890–895, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Elstein, A. Abrahamov, I. Hadas-Halpern, A. Meyer, and A. Zimran, “Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease,” Quarterly Journal of Medicine, vol. 91, no. 7, pp. 483–488, 1998. View at Google Scholar · View at Scopus
  10. D. Elstein, I. Hadas-Halpern, Y. Azuri, A. Abrahamov, Y. Bar-Ziv, and A. Zimran, “Accuracy of ultrasonography in assessing spleen and liver size in patients with Gaucher disease: comparison to computed tomographic measurements,” Journal of Ultrasound in Medicine, vol. 16, no. 3, pp. 209–211, 1997. View at Google Scholar · View at Scopus
  11. G. A. Grabowski, K. Kacena, J. A. Cole et al., “Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1,” Genetics in Medicine, vol. 11, no. 2, pp. 92–100, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Sidransky, G. M. Pastores, and M. Mori, “Dosing enzyme replacement therapy for Gaucher disease: older, but are we wiser?” Genetics in Medicine, vol. 11, no. 2, pp. 90–91, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Andersson, P. Kaplan, K. Kacena, and J. Yee, “Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1,” Pediatrics, vol. 122, no. 6, pp. 1182–1190, 2008. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Khan, T. Hangartner, N. J. Weinreb, J. S. Taylor, and P. K. Mistry, “Risk factors for fractures and avascular osteonecrosis in type 1 Gaucher disease—a study from the international collaborative Gaucher group (ICGG) Gaucher registry,” Journal of Bone and Mineral Research, vol. 27, no. 8, pp. 1839–1848, 2012. View at Google Scholar
  15. P. Stein, A. Malhotra, A. Haims, G. M. Pastores, and P. K. Mistry, “Focal splenic lesions in type I Gaucher disease are associated with poor platelet and splenic response to macrophage-targeted enzyme replacement therapy,” Journal of Inherited Metabolic Disease, vol. 33, no. 6, pp. 769–774, 2010. View at Publisher · View at Google Scholar · View at Scopus